Abstract

mRNA technologies have the potential to transform areas of medicine, including the prophylaxis of infectious diseases. The advantages for vaccines range from the acceleration of immunogen discovery to rapid response and multiple disease target manufacturing. A greater understanding of quality attributes that dictate translation efficiency, as well as a comprehensive appreciation of the importance of mRNA delivery, are influencing a new era of investment in development activities. The application of translational sciences and growing early-phase clinical experience continue to inform candidate vaccine selection. Here we review the state of the art for the prevention of infectious diseases by using mRNA and pertinent topics to the biotechnology and pharmaceutical industries.

Details

Title
The promise of mRNA vaccines: a biotech and industrial perspective
Author
Jackson, Nicholas A, C 1 ; Kester, Kent E 2   VIAFID ORCID Logo  ; Casimiro Danilo 2 ; Gurunathan Sanjay 2 ; DeRosa, Frank 3 

1  Coalition for Epidemic Preparedness Innovations (CEPI), Gibbs building, London, UK 
2  Sanofi Pasteur, Swiftwater, USA (GRID:grid.417555.7) (ISNI:0000 0000 8814 392X) 
3  Translate Bio, Lexington, USA (GRID:grid.417555.7) 
Publication year
2020
Publication date
2020
Publisher
Nature Publishing Group
e-ISSN
20590105
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1038/s41541-020-0159-8
ProQuest document ID
2376713443
Copyright
This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.